Product Description
BMS-986449, a Cereblon E3 Ligase Modulatory Drug (CELMoD™) molecular glue degrader of Helios and Eos. BMS-986449 is a potent and orally bioavailable degrader of IKZF2/4 with minimal impact on IKZF1/3 levels in regulatory T-cells as assessed by global proteomics. (Sourced from: https://aacrjournals.org/cancerres/article/85/8_Supplement_2/ND05/762481/Abstract-ND05-The-discovery-of-BMS-986449-a-highly)
Mechanisms of Action: IKZF2 Degrader, IKZF4 Degrader
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Bristol-Myers Squibb
Company Location: Eastern America
Company Founding Year: 1989
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, France, Italy, Netherlands, Spain, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Triple Negative Breast Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05888831 |
CA120-1001 | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer|Triple Negative Breast Cancer |
2026-09-30 |
2025-06-12 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2023-503484-42-00 |
CA120-1001 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2025-05-21 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|